GlassScriptPhysician profile
Prasanthi Tondapu
NPI 1023210382
$13,754.59
in general payments reported to CMS, 2019-2025
27 companies · $192 in 2025
The $192 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,375 · 2020: $6,495 · 2021: $3,294 · 2022: $68.85 · 2023: $76.24 · 2024: $254 · 2025: $192.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $480 · Education: $42.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $479.94 |
| Education | $42.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $12,442.49 | 2019-2024 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $286.38 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $215.93 | 2019-2025 | |
| Dexcom, INC. | $137.33 | 2019-2024 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $85.73 | 2019-2024 | Jardiance |
| Mannkind Corporation | $73.20 | 2022-2025 | |
| Valeritas, INC. | $58.92 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.75 | 2023-2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $42.44 | 2019 | |
| Merck Sharp & Dohme LLC | $38.75 | 2019 | |
| Amarin Pharma, INC. | $36.96 | 2019 | |
| Insulet Corporation | $29.64 | 2019 | |
| Tandem Diabetes Care, INC. | $28.17 | 2022 | |
| Abbvie INC. | $27.62 | 2023 | Vraylar |
| Pfizer INC. | $27.41 | 2024 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $24.54 | 2019 | |
| Medtronic, INC. | $17.52 | 2023 | Minimed 780g |
| Radius Health, INC. | $16.01 | 2019 | |
| Astellas Pharma US INC | $15.70 | 2024 | Veozah |
| Abbott Laboratories | $15.14 | 2019 | |
| Amgen INC. | $15.04 | 2020 | |
| Shire North American Group INC | $14.85 | 2019 | |
| Beta Bionics, INC. | $13.37 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Ibsa Pharma INC. | $12.89 | 2023 | Tirosint, Licart |
| Becton, Dickinson and Company | $11.75 | 2019 | |
| Eisai INC. | $11.54 | 2019 | |
| Corcept Therapeutics | $11.52 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Prasanthi Tondapu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.